
Prostate Health Market by Disease Type (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), Therapy Type (AR-Directed Therapies, Cytotoxic Agents, Hormone ADT), Drug Treatment Type - Global Forecast 2024-2030
Description
Prostate Health Market by Disease Type (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), Therapy Type (AR-Directed Therapies, Cytotoxic Agents, Hormone ADT), Drug Treatment Type - Global Forecast 2024-2030
The Prostate Health Market size was estimated at USD 52.13 billion in 2023 and expected to reach USD 57.48 billion in 2024, at a CAGR 10.74% to reach USD 106.49 billion by 2030.
Global Prostate Health Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Prostate Health Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Prostate Health Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Prostate Health Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Ltd..
Market Segmentation & Coverage
This research report categorizes the Prostate Health Market to forecast the revenues and analyze trends in each of the following sub-markets:
Disease Type
Benign Prostatic Hyperplasia
Prostate Cancer
Prostatitis
Therapy Type
AR-Directed Therapies
Cytotoxic Agents
Hormone ADT
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
Drug Treatment Type
5-Alpha Reductase Inhibitors
Dutasteride
Finasteride
Alpha Blockers
Alfuzosin
Doxazosin
Silodosin
Tamsulosin
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Prostate Health Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Prostate Health Market?
3. What are the technology trends and regulatory frameworks in the Prostate Health Market?
4. What is the market share of the leading vendors in the Prostate Health Market?
5. Which modes and strategic moves are suitable for entering the Prostate Health Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Prostate Health Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
- 5.1.1.2. Growing government’s initiatives for advancement in technology in diagnosis
- 5.1.1.3. Innovation in hormone therapy drugs and developments genomics and proteomics
- 5.1.2. Restraints
- 5.1.2.1. Side-effects associated with BPH medications
- 5.1.3. Opportunities
- 5.1.3.1. Increasing researches leading to development of new drugs like Rucaparib and Olaparib
- 5.1.3.2. Development of novel modality of therapy for prostate cancer
- 5.1.4. Challenges
- 5.1.4.1. Low awareness regarding prostate health
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Prostate Health Market, by Disease Type
- 6.1. Introduction
- 6.2. Benign Prostatic Hyperplasia
- 6.3. Prostate Cancer
- 6.4. Prostatitis
- 7. Prostate Health Market, by Therapy Type
- 7.1. Introduction
- 7.2. AR-Directed Therapies
- 7.3. Cytotoxic Agents
- 7.4. Hormone ADT
- 7.5. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
- 8. Prostate Health Market, by Drug Treatment Type
- 8.1. Introduction
- 8.2. 5-Alpha Reductase Inhibitors
- 8.3.1. Dutasteride
- 8.3.2. Finasteride
- 8.3. Alpha Blockers
- 8.4.1. Alfuzosin
- 8.4.2. Doxazosin
- 8.4.3. Silodosin
- 8.4.4. Tamsulosin
- 9. Americas Prostate Health Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Prostate Health Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Prostate Health Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Astellas Pharma Inc.
- 13.1.2. AstraZeneca PLC
- 13.1.3. Bayer AG
- 13.1.4. Bristol-Myers Squibb Company
- 13.1.5. Elekta AB
- 13.1.6. Eli Lilly and Company
- 13.1.7. F. Hoffmann-La Roche AG
- 13.1.8. Ferring Pharmaceuticals Inc.
- 13.1.9. GlaxoSmithKline PLC
- 13.1.10. Ipsen Limited
- 13.1.11. Merck & Co., Inc.
- 13.1.12. Novartis AG
- 13.1.13. Pfizer Inc.
- 13.1.14. Sanofi S.A.
- 13.1.15. Takeda Pharmaceutical Company Ltd.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. PROSTATE HEALTH MARKET RESEARCH PROCESS
- FIGURE 2. PROSTATE HEALTH MARKET SIZE, 2023 VS 2030
- FIGURE 3. PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PROSTATE HEALTH MARKET DYNAMICS
- FIGURE 7. PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
- FIGURE 10. PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2030 (%)
- FIGURE 12. PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.